76Bio

Tarveda Therapeutics is a biopharmaceutical company based in Watertown, MA, specializing in innovative cancer therapies. Their focus lies in developing novel treatments that target specific cancer cells, offering hope to patients with challenging forms of the disease. Utilizing cutting-edge research and technology, Tarveda Therapeutics is dedicated to advancing the field of oncology and improving outcomes for cancer patients. With a commitment to precision medicine, they strive to revolutionize cancer treatment through their groundbreaking approach.Generated from the website

Senesco Technologies is engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Its platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. The company is developing its technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. It is also researching applications of its technologies that may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma and cardiovascular disease. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Obsidian Therapeutics Inc, based in Cambridge, MA, is at the forefront of precision cell and gene therapy, utilizing its proprietary cytoDRIVE platform to engineer regulated therapeutic proteins. The company is dedicated to pioneering the next generation of engineered therapeutics to address critical patient needs. With a focus on innovative solutions, Obsidian is advancing its lead clinical program, OBX115, an engineered TIL cell therapy targeting advanced melanoma. The company’s commitment to collaboration and urgency drives its mission to improve patient outcomes through cutting-edge science and technology. Generated from the website